Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser, +22

Blood

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Pablo Umaña, Joël Joan Pierre Jean-Mairet, Radmila Moudry, +2

Nature Biotechnology

Engineered GlycoformsMedicineImmunologyImmune Checkpoint InhibitorAntineuroblastoma Igg1 +8

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Claudia Ferrara, Sandra Grau, Christiane Jäger, +9

Proceedings of the National Academy of Sciences

GlycobiologyImmunologyImmunotherapeuticsAnalytical UltracentrifugationImmune System +18

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, +19

Journal of Clinical Oncology

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara, +7

Protein Engineering Design and Selection

ImmunologyImmune RegulationImmunodominanceImmunologic MechanismImmunotherapeutics +22

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

Daniela S. Thommen, Jens Schreiner, Philipp Müller, +14

Cancer Immunology Research

Increased DysfunctionT-regulatory CellImmunologyMultiple Inhibitory ReceptorsImmune Checkpoints +16

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Christian Klein, Alfred Lammens, Wolfgang Schäfer, +6

mAbs

ImmunologyImmunodominancePathologyImmunologic MechanismAntigen Processing +16

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Maud Mayoux, Andreas Roller, Vesna Pulko, +19

Science Translational Medicine

Dc Gene SignatureTumor ImmunologyCancer ImmunosurveillancePd-l1 BlockadeMedicine +9

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl, +19

Molecular Cancer Therapeutics

Xenograft ModelsImmunologyImmune RegulationCell DeathImmunologic Mechanism +18

The Carbohydrate at FcγRIIIa Asn-162

Claudia Ferrara, Fiona Stuart, Peter Sondermann, +2

Journal of Biological Chemistry